Catalent, Inc.
- Jurisdiction
United States - ISIN
US1488061029 (CTLT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. Read full profile
Stock price
Fundamentals
- Net revenue
€3.79B - Gross margin
21.8% - EBIT
€48.05M - EBIT margin
1.3% - Net income
-€354.35M - Net margin
-9.3%
Statement period: - (published )
Dividends
No dividend payouts